Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in EVAX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Merck & Co., Inc. | 1.2M | $3.8M | 0.0% | 19.221% | 0.71% |
| 2 | Ikarian Capital, LLC | 75K | $232K | 0.0% | 1.183% | 0.02% |
| 3 | Rathbones Group PLC | 46K | $142K | 0.0% | 0.724% | 0.00% |
| 4 | CITADEL ADVISORS LLC | 37K | $113K | +105.8% | 0.579% | 0.00% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 34K | $105K | -13.8% | 0.535% | 0.00% |
| 6 | Annis Gardner Whiting Capital Advisors, LLC | 30K | $93K | 0.0% | 0.475% | 0.01% |
| 7 | J. Safra Sarasin Holding AG | 23K | $71K | — | 0.363% | 0.00% |
| 8 | RHUMBLINE ADVISERS | 22K | $68K | +0.9% | 0.346% | 0.00% |
| 9 | JANE STREET GROUP, LLC | 21K | $64K | — | 0.326% | 0.00% |
| 10 | BOOTHBAY FUND MANAGEMENT, LLC | 18K | $57K | 0.0% | 0.292% | 0.00% |
| 11 | Stonepine Capital Management, LLC | 18K | $54K | -10.9% | 0.278% | 0.01% |
| 12 | SmartHarvest Portfolios, LLC | 13K | $42K | -2.5% | 0.213% | 0.01% |
| 13 | XTX Topco Ltd | 13K | $40K | -41.5% | 0.204% | 0.00% |
| 14 | WESBANCO BANK INC | 10K | $31K | 0.0% | 0.158% | 0.00% |
| 15 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 8K | $25K | 0.0% | 0.127% | 0.00% |
| 16 | UBS Group AG | 6K | $19K | — | 0.099% | 0.00% |
| 17 | GAMMA Investing LLC | 5K | $14K | -11.3% | 0.073% | 0.00% |
| 18 | SBI Securities Co., Ltd. | 62 | $192 | 0.0% | 0.001% | 0.00% |
| 19 | BESSEMER GROUP INC | 18 | $0 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in EVAX — a direct measure of their conviction.
Filings activity in EVAX during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 19 | +12% | 25.20% | +0.78 pp | $5M | 14% |
| Q1 2026 | 17 | +21% | 24.42% | +1.93 pp | $6M | 15% |
| Q4 2025 | 14 | +75% | 22.49% | +1.42 pp | $7M | +35% |
| Q3 2025 | 8 | 11% | 21.07% | 0.05 pp | $5M | +53% |
| Q2 2025 | 9 | 18% | 21.12% | 0.34 pp | $3M | +31% |
| Q1 2025 | 11 | +0.0% | 21.46% | +18.91 pp | $2M | +266% |
| Q4 2024 | 11 | +22% | 2.55% | +0.81 pp | $1M | 60% |
| Q3 2024 | 9 | — | 1.74% | — | $2M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying EVAX stock.
Based on Q2 2026 13F filings, institutional ownership of Evaxion Biotech A/S stands at 25.2%, held across 19 reporting institutions.
Merck & Co., Inc. is the largest reported institutional holder of EVAX, with approximately 1,214,126 shares worth $0.00B as of Q2 2026.
Yes — 3 widely-followed marquee investors appear among the top 25 institutional holders of EVAX, including CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC.
Our composite Smart Money Score for EVAX is 75 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in EVAX during Q2 2026, while 1 fully exited. 1 added to existing positions and 14 trimmed.
EVAX institutional ownership rose by 0.78 percentage points quarter-over-quarter, with a net change of +2 holders.
The top 10 institutions account for 95.4% of all reported 13F value in EVAX, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.